Ranger™ Drug-Coated Balloon.

Ranger™ Drug-Coated Balloon

Backed by multiple Level-1 Randomized Controlled Trials, Ranger provides exceptional outcomes, effortless deliverability, and efficient drug transfer.
Explore product details

Reimbursement

Coding and payment guides

Configure or select a product to continue to order

Explore drug-eluting technologies

Effortless deliverability.
Efficient drug transfer.
Exceptional outcomes.

For ease, durability and effectiveness, Ranger Drug-Coated Balloon (DCB) delivers like nothing else.

Ranger™ Paclitaxel-Coated PTA Balloon Catheter.

How it works

Ranger Drug-Coated Balloon.

Boston Scientific's Ranger Drug-Coated Balloon is built on the physician preferred Sterling™ 0.014”/0.018” balloon platform with the lowest tip entry profile of any SFA DCB. For ease, durability and effectiveness, Ranger DCB delivers like nothing else.

Why choose Ranger

Detailed shot of the Ranger DCB low profile (tapered tip).

Effortless deliverability

Ranger DCB's low profile and tapered tip2 enables a smooth delivery with excellent trackability and navigation through alternative access3 sites.

Ranger's proprietary loading tool serves as the balloon and drug protector to help prevent drug loss during insertion and limit a physician's exposure to drug.

See how
Full image of the Ranger DCB.

Efficient drug transfer

TransPax™ (citrate ester + low dose paclitaxel) is a next-generation coating that enables highly efficient drug transfer into the lesion.

  • LIPOPHILIC: TransPax enables targeted and efficient delivery of low-dose paclitaxel (2 µg/mm2) into the lesion
  • HYDROPHOBIC: TransPax protects the drug from dissolving in blood prior to deployment and limits drug waste
  • The lowest amount of downstream particulates compared to other DCBs*
  • No measurable levels of pacitaxel in the bloodstream within an hour for the majority of patients*
Learn more
Near 90 percent.

Exceptional outcomes

Boston Scientific is the first company to voluntarily evaluate its Drug-Coated Balloon (DCB) in a Level-1 Randomized Controlled Trial against another DCB for comparative effectiveness. The Ranger™ DCB demonstrated similar primary patency to IN.PACT with half the total drug dose at two years and consistently achieved high primary patency—nearly 90%—at one year in the RANGER II SFA and COMPARE trials.

See the data

References:

*Gongora et al. Comparative Drug-Coated Balloon Study. JACC Cardiovasc Interv. 2015 doi.org/10.1016/j.jcin.2015.03.020
1. DRG Data, CY 2020, 0.018" PTA Balloons.
2. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Measurements taken from 6 x 120 devices for Ranger DCB, Lutonix™ 035 DCB, IN.PACT Admiral DCB and Stellarex™ 035 DCB. Lutonix 018 DCB measurements taken from 6 x 150 devices.
3. Boston Scientific Data on File. Ranger Catheter Competitive Testing Report, 92517674. Ranger diameters ≤6mm, testing done with Terumo GLIDESHEATH SLENDER™ 5F.4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.
4. COMPARE Clinical Trial 1-Year Results presented by Sabine Steiner, MD. LINC 2020. K-M Primary Patency = 88.4%. RANGER II SFA Pivotal Trial 1-Year Results presented by Marianne Brodmann. LINC 2020. K-M Primary Patency = 89.8%.

Related products

Eluvia™ Drug-Eluting Vascular Stent System Eluvia™ Drug-Eluting Vascular Stent System